Bone Metastases in Patients with Prostate Cancer: A Literature Review

  • Fang Guo 1 1 Department of Oncology, Cancer Center of People’s Liberation Army, General Hospital of Shenyang Military Region, Shenyang City, Liaoning Province, P.R.China
  • Tianhong Li 2 2 First Clinical Academy, Liaoning University of Traditional Chinese Medicine, Shenyang City, Liaoning Province, P.R.China
  • Zhendong Zheng 3 3 Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110840, P.R.China.
DOI: https://doi.org/10.18686/aem.v7i2.143
Keywords: Prostate cancer, bone metastasis, therapeutic strategy

Abstract

Prostate cancer is a major threat to men's health around the world. Bone is the most common metastasis site in patients with prostate cancer, which may lead to bone pain, pathological fracture and spinal cord compression, and it is related to various physiological or pathological factors such as age, physical condition, and previous treatment. The occurrence of bone-related events will seriously affect the quality of life of patients. In recent years, more and more people are concerned about bone metastasis of prostate cancer. Some important international cancer organizations have issued guidelines for the diagnosis and treatment of prostate cancer with bone metastasis. However, Clinicians still have some misunderstandings about bone metastasis of prostate cancer, especially selection of therapeutic strategies and the screening of appropriate drugs. Nowadays, the therapeutic strategies of prostate cancer with bone metastases mainly include primary lesions and bone metastases lesions. The former include surgery, radiotherapy, endocrine therapy, chemotherapy, immunotherapy, radiofrequency ablation and so on. And the later is made up of bone modification drug, radiopharmaceutical, lifestyle adjustment, and symptomatic analgesic treatment. The purpose of this review is to summarize the status and progression of bone metastasis in prostate cancer and to explore the best diagnosis and therapeutic strategies.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics 2017. CA Cancer J Clin 2017 Jan; 67(1): 7-30.
[2] Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: The report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497-9.
[3] Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China 2015. CA Cancer J Clin 2016 Mar-Apr; 66(2): 115-32.
[4] Nandana S, Tripathi M, Duan P, et al. Metastasis of prostate cancer can be therapeutically targeted at the tbx2-wnt signaling axis. Cancer Res 2017 Mar 15; 77(6): 1331-1344.
[5] Shibata H, Kato S, Sekine I, et al. Diagnosis and treatment of bone metastasis: comprehensive guideline of the japanese society of medical oncology, japanese orthopedic association, japanese urological association, and japanese society for radiation oncology. ESMO Open 2016 Mar 16; 1(2): e000037.
[6] Cassinello Espinosa J, González Del Alba Baamonde A, Rivera Herrero F, et al. SEOM (Spanish society of clinical oncology). SEOM guidelines for the treatment of bone metastases from solid tumours. Clin Transl Oncol 2012 Jul; 14(7): 505-11.
[7] Coleman R1, Body JJ2, Aapro M3, et al. ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014 Sep; 25 Suppl 3: iii124-37.
[8] Alibhai SMH, Zukotynski K, Walker-Dilks C, et al. Cancer care ontario genitourinary cancer disease site group. Bone health and bone-targeted therapies for prostate cancer: A programme in evidence-based care - cancer care ontario clinical practice guideline. Clin Oncol (R Coll Radiol) 2017 Jun; 29(6): 348-355.
[9] Morrissey C, Roudier MP, Dowell A, et al. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: Results from the university of washington rapid autopsy series. J Bone Miner Res 2013; 28: 333–340.
[10] Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 2003 Sep; 92(4): 379-83.
[11] Géczi L, Sinkovics I. Bone-targeted treatment in prostate cancer. Magy Onkol. 2014 Sep; 58(3): 199-203.
[12] Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 2018 May 4; 19(5). pii: E1359.
[13] Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016 Jan 2; 387(10013): 70-82.
[14] Dorff TB, Agarwal N. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian J Androl 2018 May-Jun; 20(3): 215-220.
[15] Chau A, Gardiner P, Colletti PM, et al. Diagnostic performance of 18f-fluciclovine in detection of prostate cancer bone metastases. Clin Nucl Med 2018 Jul; 43(7): e226-e231.
[16] Wei RJ, Li TY, Yang XC, et al. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Genet Mol Res 2016 Jun 3; 15(2). doi: 10.4238/gmr.15027707.
[17] Hayes AR, Brungs D, Pavlakis N. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis. PLoS One 2018 Jan 25; 13(1): e0191455.
[18] Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcif Tissue Int 2018 Feb; 102(2): 251-264.
[19] Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012 Oct; 13(10): 983-92.
[20] Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015 Feb; 16(2): 152-60.
[21] Iida K. Monotherapy versus combined androgen blockade for advanced/metastatic prostate cancer. Gan To Kagaku Ryoho 2011 Dec; 38(13): 2553-7.
[22] Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993 Mar; 149(3): 607-9.
[23] Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct 7; 351(15): 1502-12.
[24] Ndibe C, Wang CG, Sonpavde G. Corticosteroids in the management of prostate cancer: A critical review. Curr Treat Options Oncol 2015 Feb; 16(2): 6.
[25] de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010 Oct 2; 376(9747): 1147-54.
[26] Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase iii trial-firstana. J Clin Oncol 2017 Oct 1; 35(28): 3189-3197.
[27] Zustovich F, Barsanti R. Targeted α therapies for the treatment of bone metastases. Int J Mol Sci 2017 Dec 28; 19(1). pii: E74.
[28] Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011 Mar 5; 377(9768): 813-22.
[29] Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012 Jan 7; 379(9810): 39-46.
[30] Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013 Oct 20; 31(30): 3800-6.
[31] Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014 Nov; 15(12): 1397-406.
Published
2018-08-08
Issue
Vol 7 No 2 (2018)
Section
Original Research Article

Copyright (c) 2018 Fang Guo 1, Tianhong Li 2, Zhendong Zheng 3

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.